Table 1 Baseline and clinical characteristics of the study population
From: Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis
| Characteristics | Patients (n = 47) |
|---|---|
| Age at diagnosis | 62.0 [55.0–72.0] |
| Age at diagnosis | |
| > 50 years | 38 (80.9 %) |
| ≤ 50 years | 9 (19.1 %) |
| Body mass index | 26.2 [24.2–28.9] |
| Family history | 14 (29.7 %) |
| Smoker | 10 (21.3 %) |
| Alcohol intake | 10 (21.3 %) |
| Obesity | 10 (21.3 %) |
| Side affected | |
| Left | 29 (61.7 %) |
| Right | 17 (36.2 %) |
| Both | 1 (2.1 %) |
| Tumor stage | |
| I | 16 (34.0 %) |
| II | 21 (44.7 %) |
| III | 6 (12.8 %) |
| IV | 1 (2.1 %) |
| Unknown | 3 (6.4 %) |
| Histotype | |
| Ductal | 45 (95.8 %) |
| Papillary | 1 (2.1 %) |
| Mixed | 1 (2.1 %) |
| Hormone receptor positive | |
| ER | 38/43 (88.4 %) |
| PgR | 35/43 (81.4 %) |
| Both | 34/43 (79.1 %) |
| Unknown | 4/47 (8.5 %) |
| ER+/PgR- | 4/43 (9.3 %) |
| ER-/PgR+ | 1/43 (2.3 %) |
| Hormone receptor negative | 4/43 (9.3 %) |
| HER-2 positive | 11/41 (26.8 %) |
| Unknown | 6/47 (12.8 %) |
| Triple negative | 3/43 (7.0 %) |
| Nodes status | |
| Positive | 17/44 (38.6 %) |
| Negative | 27/44 (61.4 %) |
| Unknown | 3/47 (6.4 %) |
| Ki-67 high-level (cut off 20 %) | 22/34 (64.7 %) |
| Unknown | 13/47 (27.7 %) |
| Surgery | |
| Mastectomy | 40 (85.1 %) |
| Quadrantectomy | 7 (14.9 %) |
| Radiotherapy | 14 /43 (32.6 %) (4 unknown) |
| Chemotherapy | 29/41 (70.7 %) (6 unknown) |
| Endocrine therapy | 37/41 (90.2 %) (6 unknown) |
| Trastuzumab | 7/42 (16.7 %) (5 unknown) |
| Relapse | 9/40 (22.5 %) (6 unknown) |
| Other tumors | 9 (19.1 %) |
| BRCA test | |
| No | 30 (63.8 %) |
| Yes | 17 (36.2 %) |
| BRCA mutation | |
| BRCA 1 | 1 (5.9 %) |
| BRCA 2 | 5 (29.4 %) |
| Unknown variant sequence | 1 (5.9 %) |
| Negative | 10 (58.8 %) |
| Death | 7 (14.9 %) |
| No BRCA test | 4 (57.1 %) |
| BRCA 1 | 1 (14.3 %) |
| BRCA 2 | 2 (28.6 %) |
| Follow-up | Median 2660 [1065–4452] days (7.3 years) |